Targeted Therapy Drugs

Targeted Therapy Drugs: Introduction

The superiority of targetd therapy compared with chemotherapy make it a star in cancer therapy research. So a lot of researches have been conducted in this area. Many researches have achieved good results and steppped into clinical sections. Furthermore, some of the drugs have been approved by FDA, leading to great significances in cancer therapy.

Targeted Therapy Drugs: Elotuzumab

Elotuzumab, developed Bristol-Myers Squibb of New York, is a humanized monoclonal immunoglobulin G1 antibody targeting SLAMF7, which can be found on the surface of myeloma cells and natural killer lymphocytes in the immune system. It is approved on November 30, 2015 by the U.S. Food and Drug Administration for treating people with multiple myeloma who have received one to three prior medications in combination with two other therapies.

Targeted Therapy Drugs: Necitumumab

Necitumumab, developed by Eli Lilly, is a recombinant human IgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. It is applied in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).

Targeted Therapy Drugs: Daratumumab

Daratumumab, jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, by bingding to CD38 is the first monoclonal antibody approved for the treatment of multiple myeloma. It is administered as a single agent for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.

Targeted Therapy Drugs: Ramucirumab

Ramucirumab, developed by Eli Lilly, a recombinant monoclonal antibody of the IgG1 class that binds to vascular endothelial growth factor receptor-2 (VEGFR-2) and blocks the activation of the receptor. It is approved for the treatment of multiple sollid tumors: metastatic colorectal cancer, platinum-resistant metastatic non-small cell lung cancer, advanced gastric or gastroesophageal junction adenocarcinoma and gastric or gastroesophageal junction adenocarcinoma.

Targeted Therapy Drugs: Trastuzumab

Trastuzumab, developed by Genentech, Inc., a monoclonal antibody that interferes with the HER2/neu receptor. It is approved in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil), for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma, who have not received prior treatment for metastatic disease.

Targeted Therapy Drugs: Vemurafenib

Vemurafenib, developed by Hoffmann-La Roche Inc., a B-Raf enzyme inhibitor. It is approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test.

Targeted Therapy Drugs: Crizotinib

Crizotinib, developed by Pfizer, Inc., a targted therapy drug for both ALK and ROS1. It is approved to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive in 2016. And in 2013 it is also indicated for patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Targeted Therapy
What is Targeted Therapy
Targeted Therapy: Targets
Targeted Therapy for Cancer
Targeted Therapy for Kidney Cancer
Targeted Therapy for Liver Cancer
Colorectal Cancer Targeted Therapy
What is Targeted Therapy for Cancer
Targeted Therapy for Leukemia
Targeted Therapy for Pancreatic Cancer
Prostate Cancer Targeted Therapy
Targeted Therapy for Ovarian Cancer
Melanoma Targeted Therapy
Targeted Therapy for Lung Cancer
Targeted Therapy for Breast Cancer
EGFR Targeted Therapy
EGFR Targeted Therapy for Breast Cancer
EGFR Targeted Therapy for Colorectal Cancer
EGFR Targeted Therapy for Head and Neck Cancer
EGFR Targeted Therapy for Non-Small-Cell Lung Cancer
EGFR Targeted Therapy for Ovarian Cancer
EGFR Targeted Therapy for Pancreatic Cancer
HER2 Targeted Therapy
HER2 Targeted Therapy for Breast Cancer
HER2 Targeted Therapy for Colorectal Cancer
Her2 targeted therapy for Ovarian cancer
VEGF Targeted Therapy
VEGF Targeted Therapy for Breast Cancer
VEGF Targeted Therapy for Lung Cancer
VEGF Targeted Therapy for Prostate Cancer
VEGF Targeted Therapy for Colorectal Cancer
BRAF Targeted Therapy
BRAF Targeted Therapy for Melanoma
BRAF Targeted Therapy for Lung Cancer
ALK Targeted Therapy
ALK Targeted Therapy for Lung Cancer
ALK Targeted Therapy for Anaplastic Large Cell Lymphoma
Immune Checkpoint Targeted Therapy
Targeted Therapy Drugs
Targeted Therapy Drugs: Elotuzumab
Targeted Therapy Drugs: Necitumumab
Targeted Therapy Drugs: Daratumumab
Targeted Therapy Drugs: Ramucirumab
Targeted Therapy Drugs: Trastuzumab
Targeted Therapy Drugs: Vemurafenib
Targeted Therapy Drugs: Crizotinib
The Differences between Chemotherapy and Targeted Therapy
Side Effects of Targeted Therapy
Oral Targeted Therapy
Targeted Therapy Resistance
How does Targeted Therapy Work